GPC3 and hepatocellular carcinoma: NCT03198546 is a phase 1 trial testing the safety and efficacy of anti-GPC3-7 × 19 CAR-T cells (GPC3 CAR-T cells to secrete human IL-7 and CCL19) in patients with advanced hepatocellular carcinoma (HCC) expressing GPC3 [40].